Hanmi Pharm's 'Amozaltan Family' Surpasses 1 Trillion KRW in Cumulative Prescription Sales

Released in June 2009 as Korea's First Improved New Drug
Cumulative Sales of About 1.2 Billion Tablets... Accelerating Overseas Expansion

Hanmi Pharmaceutical 'Amozaltan Family' (Photo by Hanmi Pharmaceutical)

[Asia Economy Reporter Chunhee Lee] Hanmi Pharmaceutical's combination drug for hypertension treatment, the ‘Amozalatan Family,’ has surpassed cumulative prescription sales of 1 trillion KRW. This is the first achievement by a domestic pharmaceutical company with a drug independently developed in Korea.

Hanmi Pharmaceutical announced on the 27th that the Amozalatan Family, consisting of a total of 4 types and 18 dosages, achieved cumulative sales of 1.009 trillion KRW based on Ubist data up to last year. This record was achieved 12 years and 6 months after the initial launch of ‘Amozalatan’ in June 2009.

Registered as Korea’s first improved new drug in June 2009, Amozalatan is a combination drug independently developed by Hanmi Pharmaceutical. Additional components were gradually added, expanding it into the Amozalatan Family. The Amozalatan Family consists of four types: ▲ Amozalatan (Amlodipine + Losartan), an improved combination drug for hypertension treatment ▲ Amozalatan Plus, a triple combination drug adding the hypertension treatment ingredient Chlorthalidone to Amozalatan ▲ Amozalatan Q, a triple combination drug adding the dyslipidemia treatment ingredient Rosuvastatin to Amozalatan ▲ Amozalatan XQ, a quadruple combination drug adding the dyslipidemia treatment ingredient Ezetimibe to Amozalatan Q.

Since sales began, a total of approximately 1,157.76 million tablets of the Amozalatan Family have been sold. This means that since its launch, three tablets have been prescribed every second. If the tablets sold so far were lined up, they would be enough to climb Mount Everest 1,962 times and stretch 17,366 km, which is twice the width of the United States continent.

In particular, due to the nature of combination drugs, it has also contributed to reducing the National Health Insurance budget. Hanmi Pharmaceutical analyzed that the Amozalatan Family saved about 230 billion KRW in health insurance finances compared to taking imported drugs with the same ingredients separately as single agents. For example, when taking the two therapeutic ingredients contained in Amozalatan 5/100 mg as separate imported single agents, a total of 1,288 KRW (based on 2021 insurance drug price) of health insurance funds is used, whereas Amozalatan 5/100 mg costs 924 KRW per tablet, resulting in about a 28% cost reduction.

The Amozalatan Family is also accelerating its entry into overseas markets. Currently, MSD sells Amozalatan under the brand name ‘KozaXQ’ in various countries worldwide. This is the first case of a Korean pharmaceutical company’s finished drug being imported by a global pharmaceutical company and exported overseas. In Mexico, the mid-sized pharmaceutical company Silanes is marketing Amozalatan Plus and Amozalatan Q in the Latin American market.

Woo Jong-su, CEO of Hanmi Pharmaceutical, said, “The Amozalatan Family is an icon of innovation that created a new trend of improved and combination drugs in the Korean pharmaceutical industry.” He added, “While the milestone of surpassing cumulative sales of 1 trillion KRW is meaningful, the greater pride lies in providing the public with high-quality drugs they can take with confidence.” He continued, “We will do our best to contribute more significantly to public health improvement through various combination drugs developed and sold by Hanmi Pharmaceutical.”

This content was produced with the assistance of AI translation services.